This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immuneresponses.
Pheast Therapeutics is developing macrophage-focused immunotherapies to treat cancer. The company’s lead programme is targeting CD24, an immune inhibitory signal that is hijacked by cancer to suppress immune attack. How does CD24 contribute to immune evasion in ovarian cancer and triple-negative breast cancer?
As a first step, Manguso set his sights on treatments called PD-1 checkpoint inhibitors, which at the time had shown tremendous promise in clinical trials and would receive their first FDA approval in 2014. We wanted to see whether there were as yet undiscovered drug targets that would lead to amazing cancer immunotherapies,” Manguso said.
Preliminary blinded data on NVX-CoV2373 in older adults needed to proceed to Phase 3 has previously been positively reviewed by the Food and Drug Administration (FDA). Additional clinical data from the Phase 2 trial conducted in the U.S. and Australia are expected to be unblinded in Q1 and will be targeted for publication.
These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immuneresponse. Neoantigens are recognised as non-self and trigger an immuneresponse.
This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinicaldevelopment, offering promising advancements in innovative cancer treatments.
Natural killer (NK) cells are another immune cell type that, as the name suggests, also have potent cell-killing activity, and have a well-known role in the anti-tumour immuneresponse. In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immuneresponse to the tumour.
With such dramatic success, it came as no surprise that industry dove headfirst into the I-O space, working to develop second-generation I-O therapeutics to address the substantial need that still persists for many cancer patients with a range of tumor types. While early, these data demonstrate clear promise to advance this modality.
The genes unique to the severe long COVID patients were found to be associated with immune pathways such as myeloid differentiation, macrophage foam cells and lipid signalling pathways. The article mentions that TLR4 antagonists have been identified as potential candidates for repurposing long COVID treatment.
GigaGen’s single-cell recombinant technology enables the selection and replication of a highly specific and diverse antibody response, which can also be modified to create therapeutics that are more potent than those provided by a natural immuneresponse.
7,8 The discovery of these biomarkers provides valuable insights into prognosis and disease progression, while also guiding the clinicaldevelopment of new targeted immunotherapies. Next-generation approaches Antibody Drug Conjugates (ADCs) Lung cancer therapy is enhanced by advancements in ADC technology.
Our research demonstrated that GDF-15 acts as a versatile tool for tumours to inhibit the mounting of an effective antitumoral immuneresponse at various steps of its process, including antigen presentation, immune cell activation, and their migration and infiltration into the tumour.
They are currently working with Boehringer Ingelheim to further identify and develop these antibodies. They are expected to enter clinicaldevelopment later this year. ” The researchers studied the SARS-CoV-2 antibody response of 12 people who recovered from COVID-19. .”
a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced today that the U.S. APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immuneresponse. SAN CARLOS, Calif. ,
. “The emphasis in the development of cancer immunotherapies has been placed so far mainly on drugs that stimulate the adaptive immune system to attack malignant cells, in particular T lymphocytes. Unfortunately, many advanced cancer patients do not derive a durable benefit from these drugs,” said Tehila Ben-Moshe, Ph.D.,
Strong Th1 cell-mediated immuneresponses were also observed for the vaccine candidates with either adjuvant. Based on the positive Phase 1 results reported and the unprecedented need for COVID-19 vaccines, Clover and its partners are confident to enter late-stage clinicaldevelopment for both adjuvanted vaccines.
A 30-plus valent pneumococcal candidate vaccine is also in pre-clinicaldevelopment. We look forward to working with the many talented people at Affinivax to combine our industry-leading development, manufacturing, and commercialisation capabilities to make this exciting new technology available to those in need.”
A 30-plus valent pneumococcal candidate vaccine is also in pre-clinicaldevelopment. We look forward to working with the many talented people at Affinivax to combine our industry-leading development, manufacturing, and commercialisation capabilities to make this exciting new technology available to those in need.”.
To be therapeutically useful, antigenic peptides must be presented in a way that allows immuneresponses to destroy cancer cells without causing unacceptable damage to healthy tissue. Therefore, therapeutically useful tumour antigens represent a tiny fraction of the genes expressed by a tumour cell.
“KSQ’s CRISPRomics discovery platform is a powerful technology to help us identify novel targets in line with our immuno-oncology strategy,” said Loïc Vincent, Head, Oncology Drug Discovery Unit and Immunology Unit at Takeda. Takeda will assume responsibility for funding all development and commercialization activities.
Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 has advanced into the combination therapy stage of the ongoing Phase 1 trial. SYNB1891 is being evaluated in a Phase 1 clinical trial. CAMBRIDGE, Mass. , 14, 2020 /PRNewswire/ — Synlogic, Inc.
Food and Drug Administration (FDA) gave the go-ahead for the company to initiate a Phase I trial of PRGN-2012 in adults with recurrent RRP. The drug is a first-in-class, off-the-shelf AdenoVerse immunotherapy. The National Institutes of Health (NIH) is planning on taking over manufacturing and clinicaldevelopment.
(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. About Fast Track Designation.
(Nasdaq: RIGL) today announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel’s R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. vice president of immunology at Lilly. About Rigel.
We are advancing the clinicaldevelopment of mRNA-1273 with our Phase 3 COVE study, which is now fully enrolled with a representative demography of participants across ages, ethnicities and high-risk populations. About Moderna.
We are very honored to have someone of Dr. Zeldis’ caliber lead our scientific research and clinicaldevelopment teams. At NexImmune, he will oversee all aspects of research and development. The backbone of NexImmune’s approach is its proprietary Artificial Immune Modulation (AIM TM ) nanoparticle technology platform.
The company plans to tackle the existing challenges of precision medicine with a three-prong approach – developing better medicines for known cancer-driving mutations, developingdrugs for targets previously thought to be undruggable, and finding new, untapped targets that could lead to even better drugs.
(Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ADI-001, an allogeneic gamma delta (??)
Mirati Therapeutics is a San Diego -based late-stage biotechnology company relentlessly focused on translating drug discovery and research into new treatments for patients by advancing and delivering novel therapeutics that target the genetic and immunologic drivers of cancer. About Mirati Therapeutics.
The company is using its pioneering FasTCAR and TruUCAR technology platforms to discover and develop breakthrough cell therapies. The compound was developed in the laboratory of Richard Childs, chief of the Laboratory of Transplantation Immunotherapy with the National Heart, Lung, and Blood Institute (NHLBI).
“Since immune checkpoint inhibitors were introduced more than a decade ago, they have played a transformational role in treating cancers with high unmet need, and most importantly, helping people with cancer live longer,” said Samit Hirawat, M.D. executive vice president, chief medical officer, Global DrugDevelopment, Bristol Myers Squibb.
The acquisition complements Gilead’s existing clinicaldevelopment priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. Both programs have the potential to address multiple indications, offering broad development opportunities alone and in combination with Gilead’s portfolio.
Additionally, chronic disease, cancer and neurodegenerative disorders like Alzheimer’s were top of mind last year for diagnostics and drug R&D teams alike. These same challenges and needs also extend from research and discovery to clinicaldevelopment.
The pCR data from CheckMate -816 were presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, and the EFS results will be presented in a clinical trials plenary session at the AACR Annual Meeting 2022 on April 11, 2022, beginning at 10:15 a.m. CT, in New Orleans, Louisiana. About Opdivo.
Learning from Past Failures to Drive Toward a More Durable ImmuneResponse Following the initial clinical successes of blocking inhibitory receptors, like CTLA4 and PD1, many in the immuno-oncology field explored the potential to further enhance anti-tumor immunity by simultaneously enhancing co-stimulatory pathways.
. “This clinical trial approval sets the stage to further broaden BioInvent’s promising clinical pipeline. BT-001 is our fourth program in clinicaldevelopment. We are very excited to move forward this unique oncolytic virus which combines multiple, clinically proven mechanisms of action into a single drug.
Delivery of viral antigens in potent vaccine vectors to elicit a strong immuneresponse is a cornerstone of successful infectious disease vaccines,” said Karin Jooss, PhD, Executive Vice President of Research and Chief Scientific Officer of Gritstone.
Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. Scientists will be testing a drug class targeting the C-reactive protein (CRP) marker of acute inflammation in the body. They’ll use software that searches available drugs, as well as drug-like compounds.
FDA finalizes new guidance on nonclinical assessment of potential immunotoxicity Late last week the FDA released a final guidance document containing recommendations on the nonclinical assessment of potential immunotoxicity for drugs and certain biologics.
producing CD8+ T cell responses, which is thought to promote an anti-viral effect. In a preclinical murine model, a single IM immunization of BNT162b2 (0.2, CD4+ and CD8+ T-cells from splenocytes isolated from BNT162b2-immunized mice were strongly positive for IFN?
Highly innovative first-in-class study for treating COVID-19 disease with nasally administered drug.
Clinical Data Expected by End of Year.
Furthermore, nasal anti-CD3 dampens cytotoxic CD8 T cell responses shown to cause lung damage in COVID-19.
Dr Howard Weiner, who is the Robert L.
(NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. Food and Drug Administration (FDA) in high-risk patients who have confirmed COVID-19 but are not currently hospitalized.
Barber’s work will give Kiromic a significant acceleration in the clinicaldevelopment of its therapy platform and an even more significant advantage over its competitors. Chimeric PD-1 T-cells also release cytokines to further initiate immuneresponses to eradicate the tumor cells. “We believe Prof.
T cell immuneresponses elicited by BNT162b2 are being evaluated in the German study and the companies expect to submit the data for peer review and potential publication. trial and we look forward to sharing T cell immuneresponse data from the German trial in the near future.”. “It View the full release here: [link].
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content